Schedule 13D ownership disclosure
MATINAS BIOPHARMA HLDGS INC
Common Stock, $0.0001 par value per share · CUSIP: 576810303
Event date: 2025-02-13
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Sanitam Partners LLCReported CIK 0002056830
Shares: 1,016,888 · Class: 19.99%
- STERN ADAM KReported CIK 0001403497
Shares: 1,227,575 · Class: 24.1%
- HEZBAY Holdings LLC
Shares: 1,016,888 · Class: 19.99%
- Ari Kluger
Shares: 1,016,888 · Class: 19.99%
- Platinum Point Capital, LLCReported CIK 0001845706
Shares: 1,016,888 · Class: 19.99%
- Brian Freifeld
Shares: 1,016,888 · Class: 19.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001477932-25-001179
- Form type
- SCHEDULE 13D
- Filer
- Matinas BioPharma Holdings, Inc.
- CIK
- CIK 1582554
- Filed
- Feb 21, 2025
- Reporting period
- Feb 13, 2025
- Description
- Schedule 13D beneficial ownership